Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer

Arthur Cho, Jin Hur, Yong Wha Moon, Sae Rom Hong, Young Joo Suh, Yun Jung Kim, Dong Jin Im, Yoo Jin Hong, Hye Jeong Lee, Young Jin Kim, Hyo Sup Shim, Jae Seok Lee, Joo Hang Kim, Byoung Wook Choi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: EGFR mutation-induced cell proliferation causes changes in tumor biology and tumor metabolism, which may reflect tumor marker concentration and 18F-FDG uptake on PET/CT. Direct aspirates of primary lung tumors contain different concentrations of tumor markers than serum tumor markers, and may correlate better with EGFR mutation than serum tumor markers. The purpose of this study is to investigate an association between cytologic tumor markers and FDG uptake with EGFR mutation status in non-small cell lung cancer (NSCLC). Methods: We prospectively collected tumor aspirates of 61 patients who underwent EGFR mutation analysis. Serum and cytologic CYFRA 21-1, CEA, and SCCA levels were measured and correlated with EGFR gene mutations. FDG PET/CT was performed on 58 patients for NSCLC staging, and SUV was correlated with EGFR mutation status. Results: Thirty (50 %) patients had EGFR mutation and 57 patients had adenocarcinoma subtype. Univariate analysis showed that female gender, never smoker, high levels of cytologic CYFRA 21-1 (c-CYFRA) and lower maximum standard uptake value (SUVmax) were correlated with EGFR mutations. ROC generated cut-off values of 20.8 ng/ml for c-CYFRA and SUVmax of 9.6 showed highest sensitivity for EGFR mutation detection. Multivariate analysis revealed that female gender [hazard ratio (HR): 18.15, p = 0.025], higher levels of c-CYFRA (HR: 7.58, and lower SUVmax (HR: 0.08, p = 0.005) were predictive of harboring EGFR mutation. Conclusions: The cytologic tumor marker c-CYFRA was positively associated with EGFR mutations in NSCLC. EGFR mutation-positive NSCLCs have relatively lower glycolysis compared with NSCLCs without EGFR mutation.

Original languageEnglish
Article number224
JournalBMC cancer
Volume16
Issue number1
DOIs
Publication statusPublished - 2016 Mar 16

Fingerprint

erbB-1 Genes
Fluorodeoxyglucose F18
Tumor Biomarkers
Non-Small Cell Lung Carcinoma
Mutation
Neoplasms
Biomarkers
Neoplasm Staging
Glycolysis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Cho, A., Hur, J., Moon, Y. W., Hong, S. R., Suh, Y. J., Kim, Y. J., ... Choi, B. W. (2016). Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer. BMC cancer, 16(1), [224]. https://doi.org/10.1186/s12885-016-2251-z
Cho, Arthur ; Hur, Jin ; Moon, Yong Wha ; Hong, Sae Rom ; Suh, Young Joo ; Kim, Yun Jung ; Im, Dong Jin ; Hong, Yoo Jin ; Lee, Hye Jeong ; Kim, Young Jin ; Shim, Hyo Sup ; Lee, Jae Seok ; Kim, Joo Hang ; Choi, Byoung Wook. / Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer. In: BMC cancer. 2016 ; Vol. 16, No. 1.
@article{8117f0b193c742a7b165996ae8cc426e,
title = "Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer",
abstract = "Background: EGFR mutation-induced cell proliferation causes changes in tumor biology and tumor metabolism, which may reflect tumor marker concentration and 18F-FDG uptake on PET/CT. Direct aspirates of primary lung tumors contain different concentrations of tumor markers than serum tumor markers, and may correlate better with EGFR mutation than serum tumor markers. The purpose of this study is to investigate an association between cytologic tumor markers and FDG uptake with EGFR mutation status in non-small cell lung cancer (NSCLC). Methods: We prospectively collected tumor aspirates of 61 patients who underwent EGFR mutation analysis. Serum and cytologic CYFRA 21-1, CEA, and SCCA levels were measured and correlated with EGFR gene mutations. FDG PET/CT was performed on 58 patients for NSCLC staging, and SUV was correlated with EGFR mutation status. Results: Thirty (50 {\%}) patients had EGFR mutation and 57 patients had adenocarcinoma subtype. Univariate analysis showed that female gender, never smoker, high levels of cytologic CYFRA 21-1 (c-CYFRA) and lower maximum standard uptake value (SUVmax) were correlated with EGFR mutations. ROC generated cut-off values of 20.8 ng/ml for c-CYFRA and SUVmax of 9.6 showed highest sensitivity for EGFR mutation detection. Multivariate analysis revealed that female gender [hazard ratio (HR): 18.15, p = 0.025], higher levels of c-CYFRA (HR: 7.58, and lower SUVmax (HR: 0.08, p = 0.005) were predictive of harboring EGFR mutation. Conclusions: The cytologic tumor marker c-CYFRA was positively associated with EGFR mutations in NSCLC. EGFR mutation-positive NSCLCs have relatively lower glycolysis compared with NSCLCs without EGFR mutation.",
author = "Arthur Cho and Jin Hur and Moon, {Yong Wha} and Hong, {Sae Rom} and Suh, {Young Joo} and Kim, {Yun Jung} and Im, {Dong Jin} and Hong, {Yoo Jin} and Lee, {Hye Jeong} and Kim, {Young Jin} and Shim, {Hyo Sup} and Lee, {Jae Seok} and Kim, {Joo Hang} and Choi, {Byoung Wook}",
year = "2016",
month = "3",
day = "16",
doi = "10.1186/s12885-016-2251-z",
language = "English",
volume = "16",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

Cho, A, Hur, J, Moon, YW, Hong, SR, Suh, YJ, Kim, YJ, Im, DJ, Hong, YJ, Lee, HJ, Kim, YJ, Shim, HS, Lee, JS, Kim, JH & Choi, BW 2016, 'Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer', BMC cancer, vol. 16, no. 1, 224. https://doi.org/10.1186/s12885-016-2251-z

Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer. / Cho, Arthur; Hur, Jin; Moon, Yong Wha; Hong, Sae Rom; Suh, Young Joo; Kim, Yun Jung; Im, Dong Jin; Hong, Yoo Jin; Lee, Hye Jeong; Kim, Young Jin; Shim, Hyo Sup; Lee, Jae Seok; Kim, Joo Hang; Choi, Byoung Wook.

In: BMC cancer, Vol. 16, No. 1, 224, 16.03.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer

AU - Cho, Arthur

AU - Hur, Jin

AU - Moon, Yong Wha

AU - Hong, Sae Rom

AU - Suh, Young Joo

AU - Kim, Yun Jung

AU - Im, Dong Jin

AU - Hong, Yoo Jin

AU - Lee, Hye Jeong

AU - Kim, Young Jin

AU - Shim, Hyo Sup

AU - Lee, Jae Seok

AU - Kim, Joo Hang

AU - Choi, Byoung Wook

PY - 2016/3/16

Y1 - 2016/3/16

N2 - Background: EGFR mutation-induced cell proliferation causes changes in tumor biology and tumor metabolism, which may reflect tumor marker concentration and 18F-FDG uptake on PET/CT. Direct aspirates of primary lung tumors contain different concentrations of tumor markers than serum tumor markers, and may correlate better with EGFR mutation than serum tumor markers. The purpose of this study is to investigate an association between cytologic tumor markers and FDG uptake with EGFR mutation status in non-small cell lung cancer (NSCLC). Methods: We prospectively collected tumor aspirates of 61 patients who underwent EGFR mutation analysis. Serum and cytologic CYFRA 21-1, CEA, and SCCA levels were measured and correlated with EGFR gene mutations. FDG PET/CT was performed on 58 patients for NSCLC staging, and SUV was correlated with EGFR mutation status. Results: Thirty (50 %) patients had EGFR mutation and 57 patients had adenocarcinoma subtype. Univariate analysis showed that female gender, never smoker, high levels of cytologic CYFRA 21-1 (c-CYFRA) and lower maximum standard uptake value (SUVmax) were correlated with EGFR mutations. ROC generated cut-off values of 20.8 ng/ml for c-CYFRA and SUVmax of 9.6 showed highest sensitivity for EGFR mutation detection. Multivariate analysis revealed that female gender [hazard ratio (HR): 18.15, p = 0.025], higher levels of c-CYFRA (HR: 7.58, and lower SUVmax (HR: 0.08, p = 0.005) were predictive of harboring EGFR mutation. Conclusions: The cytologic tumor marker c-CYFRA was positively associated with EGFR mutations in NSCLC. EGFR mutation-positive NSCLCs have relatively lower glycolysis compared with NSCLCs without EGFR mutation.

AB - Background: EGFR mutation-induced cell proliferation causes changes in tumor biology and tumor metabolism, which may reflect tumor marker concentration and 18F-FDG uptake on PET/CT. Direct aspirates of primary lung tumors contain different concentrations of tumor markers than serum tumor markers, and may correlate better with EGFR mutation than serum tumor markers. The purpose of this study is to investigate an association between cytologic tumor markers and FDG uptake with EGFR mutation status in non-small cell lung cancer (NSCLC). Methods: We prospectively collected tumor aspirates of 61 patients who underwent EGFR mutation analysis. Serum and cytologic CYFRA 21-1, CEA, and SCCA levels were measured and correlated with EGFR gene mutations. FDG PET/CT was performed on 58 patients for NSCLC staging, and SUV was correlated with EGFR mutation status. Results: Thirty (50 %) patients had EGFR mutation and 57 patients had adenocarcinoma subtype. Univariate analysis showed that female gender, never smoker, high levels of cytologic CYFRA 21-1 (c-CYFRA) and lower maximum standard uptake value (SUVmax) were correlated with EGFR mutations. ROC generated cut-off values of 20.8 ng/ml for c-CYFRA and SUVmax of 9.6 showed highest sensitivity for EGFR mutation detection. Multivariate analysis revealed that female gender [hazard ratio (HR): 18.15, p = 0.025], higher levels of c-CYFRA (HR: 7.58, and lower SUVmax (HR: 0.08, p = 0.005) were predictive of harboring EGFR mutation. Conclusions: The cytologic tumor marker c-CYFRA was positively associated with EGFR mutations in NSCLC. EGFR mutation-positive NSCLCs have relatively lower glycolysis compared with NSCLCs without EGFR mutation.

UR - http://www.scopus.com/inward/record.url?scp=84960862171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960862171&partnerID=8YFLogxK

U2 - 10.1186/s12885-016-2251-z

DO - 10.1186/s12885-016-2251-z

M3 - Article

C2 - 26979333

AN - SCOPUS:84960862171

VL - 16

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 224

ER -